🇺🇸 FDA

Drug profile · INN

nateglinide

TRAZEC

approved A10BX03
US status
approved
Patents linked
5
News articles
0

Quick answer

nateglinide (TRAZEC) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN nateglinide
Brand TRAZEC
Route ORAL
Formulation TABLET
ATC code A10BX03
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 7534913

    Crystalline form of nateglinide

    Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7420084

    Polymorphic forms of nateglinide

    Expires Mon Aug 28 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7358390

    Polymorphic forms of nateglinide

    Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7148376

    Polymorphic forms of nateglinide

    Expires Mon Dec 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 6861553

    Process for preparing nateglinide and intermediates thereof

    Expires Mon Feb 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is nateglinide?

nateglinide (TRAZEC) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for nateglinide?

TRAZEC is a marketed brand name for nateglinide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of nateglinide?

nateglinide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.